Abnormalities of the endosomal–lysosomal network (ELN) are a signature feature of
Alzheimer's disease (AD). These include the earliest known cytopathology that is specific to …

Alzheimer's dementia (AD) is increasingly being recognized as one of the most important
medical and social problems in older people in industrialized and non-industrialized …

Alzheimer's disease (AD) is a debilitating neurodegenerative disease that is affecting an
increasing number of people. It is characterized by the accumulation of amyloid-β and tau …

Alzheimer's disease (AD) 1− 3 is the most common form of dementia (estimated∼ 50− 60%
of all cases), associated with loss of memory (in particular episodic memory), cognitive …

Alzheimer's disease (AD) currently presents one of the biggest healthcare issues in the
developed countries. There is no effective treatment capable of slowing down disease …

Amyloid plaques and tau tangles are common pathological hallmarks for Alzheimer's
disease (AD); however, reducing Aβ production failed to relieve the symptoms of AD …

Current approved drug treatments for Alzheimer disease (AD) include cholinesterase
inhibitors (donepezil, rivastigmine, galantamine) and the NMDA receptor antagonist …

The “amyloid hypothesis” has dominated Alzheimer research for more than 20 years, and
proposes that amyloid is the toxic cause of neural/synaptic damage and dementia. If correct …

T cells, the critical immune cells of the adaptive immune system, are often dysfunctional in
Alzheimer's disease (AD) and are involved in AD pathology. Reports highlight …

Brain aging is central to late-onset Alzheimer's disease (LOAD), although the mechanisms
by which it occurs at protein or cellular levels are not fully understood. Alzheimer's disease is …